Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab

[1] Perou CM(2000)Molecular portraits of human breast tumours Nature 406 747-752

[2] Goldhirsch A(2011)Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1747

[3] Cheang MC(2009)Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736-750

[4] Eroles P(2012)Molecular biology in breast cancer: intrinsic subtypes and signaling pathways Cancer Treat Rev 38 698-707

[5] Sweeney C(2014)Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics Cancer Epidemiol Biomark Prev 23 714-724

[6] Carey LA(2006)Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492-2502

[7] Onitilo AA(2009)Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 4-13

[8] Kennecke H(2010)Metastatic behavior of breast cancer subtypes J Clin Oncol 28 3271-3277

[9] Vaz-Luis I(2012)Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study Breast Cancer Res 14 R129-1691

[10] Ribelles N(2013)Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index Breast Cancer Res 15 R98-841

[1] Perou CM(2000)Molecular portraits of human breast tumours Nature 406 747-752

[2] Goldhirsch A(2011)Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1747

[3] Cheang MC(2009)Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736-750

[4] Eroles P(2012)Molecular biology in breast cancer: intrinsic subtypes and signaling pathways Cancer Treat Rev 38 698-707

[5] Sweeney C(2014)Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics Cancer Epidemiol Biomark Prev 23 714-724

[6] Carey LA(2006)Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492-2502

[7] Onitilo AA(2009)Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 4-13

[8] Kennecke H(2010)Metastatic behavior of breast cancer subtypes J Clin Oncol 28 3271-3277

[9] Vaz-Luis I(2012)Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study Breast Cancer Res 14 R129-1691

[10] Ribelles N(2013)Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index Breast Cancer Res 15 R98-841